BBIO · BridgeBio Pharma Inc. Common Stock
View on chartInsiders & Stakes
| VIKING GLOBAL INVESTORS LP 10% Owner | ▼ Sell | Open Market | 18,555,375 Shares held | 6/27/2025 | View profile |
| BridgeBio Pharma LLC | ▼ Sell | Other | 14,589,846 Shares held | 10/10/2025 | View profile |
| KKR Genetic Disorder L.P. | ▼ Sell | Open Market | 13,260,971 Shares held | 5/12/2025 | View profile |
| Charles J. Homcy Director | ▲ Buy | Grant | 919,876 Shares held | 6/22/2026 | View profile |
| Neil Kumar Chief Executive Officer | ▼ Sell | Open Market | 495,686 Shares held | 9/17/2026 | View profile |
| Thomas Trimarchi President and COO | ▼ Sell | Tax Withholding | 336,529 Shares held | 8/16/2026 | View profile |
| Ali J. Satvat Director | ▲ Buy | Grant | 169,983 Shares held | 6/22/2026 | View profile |
| Maricel Apuli Chief Accounting Officer | ▼ Sell | Tax Withholding | 122,687 Shares held | 8/16/2026 | View profile |
| Brian C. Stephenson See Remarks | ▼ Sell | Open Market | 102,464 Shares held | 2/25/2025 | View profile |
| Richard H. Scheller Director | ▼ Sell | Tax Withholding | 53,822 Shares held | 2/16/2023 | View profile |
| Fred Hassan Director | ▲ Buy | Grant | 29,879 Shares held | 6/22/2026 | View profile |
| Andrea Ellis Director | ▼ Sell | Open Market | 22,579 Shares held | 7/9/2026 | View profile |
| Ronald J. Daniels Director | ▲ Buy | Grant | 20,981 Shares held | 6/22/2026 | View profile |
| James C. Momtazee Director | ▲ Buy | Grant | 19,070 Shares held | 6/22/2026 | View profile |
| Andrew Lo Director | ▲ Buy | Grant | 18,079 Shares held | 6/22/2026 | View profile |
| Brent L. Saunders Director | ▲ Buy | Open Market | 17,600 Shares held | 12/29/2021 | View profile |
| Randal W. Scott Director | ▼ Sell | Open Market | 11,589 Shares held | 5/15/2026 | View profile |
| Eric Aguiar Director | ▲ Buy | Grant | 10,579 Shares held | 6/22/2026 | View profile |
| Frank McCormick Director | ▲ Buy | Grant | 10,579 Shares held | 6/22/2026 | View profile |
| Douglas A. Dachille Director | ▲ Buy | Grant | 10,579 Shares held | 6/22/2026 | View profile |
| Hannah Valantine Director | ▼ Sell | Open Market | 9,259 Shares held | 6/23/2026 | View profile |
| Jennifer E. Cook Director | ▼ Sell | Open Market | 8,383 Shares held | 7/9/2026 | View profile |
Transaction History
| Neil Kumar | ▼ Sell | Open Market | 8,721 | $602K | 9/17/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,279 | $89K | 9/17/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,100 | $679K | 8/19/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,800 | $152K | 8/19/2026 |
| Neil Kumar | ▼ Sell | Open Market | 100 | $9K | 8/19/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,900 | $154K | 8/18/2026 |
| Neil Kumar | ▼ Sell | Open Market | 17,279 | $1.4M | 8/18/2026 |
| Neil Kumar | ▼ Sell | Open Market | 14,602 | $1.2M | 8/18/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,199 | $100K | 8/18/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 6,520 | — | 8/16/2026 |
| Neil Kumar | ▼ Sell | Tax Withholding | 36,237 | $2.9M | 8/16/2026 |
| Maricel Apuli | ▼ Sell | Tax Withholding | 4,714 | $376K | 8/16/2026 |
| Thomas Trimarchi | ▼ Sell | Tax Withholding | 22,781 | $1.8M | 8/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 33,544 | — | 8/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 19,599 | — | 8/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 11,554 | — | 8/16/2026 |
| Maricel Apuli | ▼ Sell | Open Market | 2,000 | $160K | 7/30/2026 |
| Andrea Ellis | ▲ Buy | Option Exercise | 17,167 | $288K | 7/9/2026 |
| Andrea Ellis | ▼ Sell | Open Market | 17,167 | $1.4M | 7/9/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 19,000 | $161K | 7/9/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 112,422 | $3.3M | 7/9/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 17,167 | $288K | 7/9/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 36,167 | $3.0M | 7/9/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 112,422 | $10.1M | 7/9/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 20,000 | $169K | 6/24/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 17,167 | $288K | 6/24/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 37,167 | $2.6M | 6/24/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 2,196 | $151K | 6/23/2026 |
| Hannah Valantine | ▼ Sell | Open Market | 2,196 | $151K | 6/23/2026 |
| Jennifer E. Cook | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Hannah Valantine | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Hannah Valantine | ▲ Buy | Option Exercise | 2,808 | $117K | 6/22/2026 |
| Hannah Valantine | ▼ Sell | Open Market | 2,808 | $191K | 6/22/2026 |
| Andrew Lo | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Charles J. Homcy | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Eric Aguiar | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Ronald J. Daniels | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Douglas A. Dachille | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Ali J. Satvat | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Andrea Ellis | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Fred Hassan | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| James C. Momtazee | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Frank McCormick | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 |
| Charles J. Homcy | ▼ Sell | Tax Withholding | 788 | $52K | 6/20/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 65,921 | $557K | 6/15/2026 |
| Jennifer E. Cook | ▲ Buy | Option Exercise | 17,167 | $288K | 6/15/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 88,737 | $5.9M | 6/15/2026 |
| Jennifer E. Cook | ▼ Sell | Open Market | 1,503 | $101K | 6/15/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,147 | $480K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,437 | $573K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 4,416 | $305K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,148 | $480K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,437 | $573K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 4,415 | $304K | 6/5/2026 |
| Neil Kumar | ▼ Sell | Open Market | 2,200 | $145K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,429 | $95K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 15,921 | $1.1M | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 450 | $31K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 2,200 | $145K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,429 | $95K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 15,921 | $1.1M | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 450 | $31K | 6/4/2026 |
| Neil Kumar | ▼ Sell | Open Market | 2,256 | $152K | 5/21/2026 |
| Neil Kumar | ▼ Sell | Open Market | 6,725 | $459K | 5/21/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,072 | $351K | 5/21/2026 |
| Neil Kumar | ▼ Sell | Open Market | 11,250 | $793K | 5/21/2026 |
| Neil Kumar | ▼ Sell | Open Market | 800 | $57K | 5/21/2026 |
| Thomas Trimarchi | ▼ Sell | Open Market | 3,195 | $211K | 5/18/2026 |
| Thomas Trimarchi | ▼ Sell | Open Market | 10,456 | $678K | 5/18/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 33,544 | — | 5/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 19,599 | — | 5/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 11,553 | — | 5/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 6,519 | — | 5/16/2026 |
| Neil Kumar | ▼ Sell | Tax Withholding | 36,236 | $2.4M | 5/16/2026 |
| Maricel Apuli | ▼ Sell | Tax Withholding | 4,714 | $312K | 5/16/2026 |
| Thomas Trimarchi | ▼ Sell | Tax Withholding | 22,781 | $1.5M | 5/16/2026 |
| Randal W. Scott | ▲ Buy | Option Exercise | 10,000 | $168K | 5/15/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 6,200 | $413K | 5/15/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 2,088 | $141K | 5/15/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 1,512 | $103K | 5/15/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 200 | $14K | 5/15/2026 |
| Neil Kumar | ▼ Sell | Open Market | 13,973 | $931K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,077 | $342K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 950 | $65K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 13,974 | $931K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,076 | $342K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 950 | $65K | 5/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 450 | $31K | 5/7/2026 |
| Neil Kumar | ▼ Sell | Open Market | 11,217 | $757K | 5/7/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,334 | $570K | 5/7/2026 |
| Neil Kumar | ▼ Sell | Open Market | 449 | $31K | 5/7/2026 |
| Neil Kumar | ▼ Sell | Open Market | 11,217 | $757K | 5/7/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,333 | $570K | 5/7/2026 |
| Maricel Apuli | ▼ Sell | Open Market | 2,000 | $143K | 4/30/2026 |
| Neil Kumar | ▼ Sell | Open Market | 20,000 | $1.5M | 4/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 20,000 | $1.5M | 4/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,200 | $530K | 4/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,300 | $395K | 4/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,500 | $567K | 4/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,072 | $521K | 4/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,128 | $382K | 4/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,800 | $589K | 4/9/2026 |
| Maricel Apuli | ▲ Buy | Grant | 14,170 | $0 | 3/18/2026 |
| Thomas Trimarchi | ▲ Buy | Grant | 59,041 | $0 | 3/18/2026 |
| Neil Kumar | ▼ Sell | Open Market | 9,690 | $662K | 3/13/2026 |
| Neil Kumar | ▼ Sell | Open Market | 10,310 | $713K | 3/13/2026 |
| Neil Kumar | ▼ Sell | Open Market | 10,241 | $700K | 3/13/2026 |
| Neil Kumar | ▼ Sell | Open Market | 9,759 | $676K | 3/13/2026 |
| Neil Kumar | ▼ Sell | Open Market | 14,337 | $982K | 3/12/2026 |
| Neil Kumar | ▼ Sell | Open Market | 13,885 | $951K | 3/12/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,815 | $403K | 3/12/2026 |
| Neil Kumar | ▼ Sell | Open Market | 300 | $21K | 3/12/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,363 | $372K | 3/12/2026 |
| Neil Kumar | ▼ Sell | Open Market | 300 | $21K | 3/12/2026 |
| Hannah Valantine | ▲ Buy | Option Exercise | 8,671 | $237K | 3/10/2026 |
| Hannah Valantine | ▼ Sell | Open Market | 8,671 | $624K | 3/10/2026 |
| Andrea Ellis | ▲ Buy | Option Exercise | 64,921 | $549K | 3/4/2026 |
| Andrea Ellis | ▼ Sell | Open Market | 64,921 | $4.2M | 3/4/2026 |
| Hannah Valantine | ▲ Buy | Option Exercise | 25,484 | $1.2M | 2/27/2026 |
| Hannah Valantine | ▼ Sell | Open Market | 14,584 | $978K | 2/27/2026 |
| Hannah Valantine | ▼ Sell | Open Market | 10,900 | $739K | 2/27/2026 |
| Maricel Apuli | ▼ Sell | Open Market | 2,000 | $132K | 2/26/2026 |
| Neil Kumar | ▼ Sell | Open Market | 18,923 | $1.3M | 2/19/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,528 | $615K | 2/19/2026 |
| Neil Kumar | ▼ Sell | Open Market | 602 | $44K | 2/19/2026 |
| Maricel Apuli | ▼ Sell | Open Market | 510 | $38K | 2/17/2026 |
| Thomas Trimarchi | ▼ Sell | Open Market | 13,400 | $1.0M | 2/17/2026 |
| Thomas Trimarchi | ▼ Sell | Open Market | 200 | $15K | 2/17/2026 |
| Randal W. Scott | ▲ Buy | Option Exercise | 10,000 | $168K | 2/17/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 1,900 | $141K | 2/17/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 4,793 | $362K | 2/17/2026 |
| Randal W. Scott | ▼ Sell | Open Market | 3,307 | $251K | 2/17/2026 |
| Maricel Apuli | ▼ Sell | Tax Withholding | 4,349 | $327K | 2/16/2026 |
| Thomas Trimarchi | ▼ Sell | Tax Withholding | 18,819 | $1.4M | 2/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 33,544 | — | 2/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 19,600 | — | 2/16/2026 |
| Neil Kumar | ▲ Buy | Option Exercise | 11,554 | — | 2/16/2026 |
| Neil Kumar | ▼ Sell | Tax Withholding | 30,970 | $2.3M | 2/16/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,806 | $552K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 3,716 | $265K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 4,484 | $326K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 3,994 | $293K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 7,860 | $556K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 3,775 | $270K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 4,404 | $320K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 3,961 | $290K | 2/11/2026 |
| Neil Kumar | ▼ Sell | Open Market | 14,201 | $1.0M | 2/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,799 | $419K | 2/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 14,040 | $1.0M | 2/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 5,960 | $431K | 2/10/2026 |
| Neil Kumar | ▼ Sell | Open Market | 6,955 | $534K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 10,519 | $816K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 375 | $29K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,401 | $106K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 6,067 | $464K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 10,677 | $827K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 1,855 | $145K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 2,151 | $163K | 1/9/2026 |
| Neil Kumar | ▼ Sell | Open Market | 400 | $30K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 300 | $23K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 11,515 | $848K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,085 | $601K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 11,565 | $852K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 8,135 | $605K | 1/8/2026 |
| Neil Kumar | ▼ Sell | Open Market | 28,311 | $2.1M | 12/15/2025 |
| Neil Kumar | ▼ Sell | Open Market | 1,700 | $128K | 12/15/2025 |
| Thomas Trimarchi | ▼ Sell | Tax Withholding | 13,826 | $1.0M | 12/12/2025 |
| Neil Kumar | ▼ Sell | Tax Withholding | 30,964 | $2.3M | 12/12/2025 |
| Maricel Apuli | ▼ Sell | Tax Withholding | 2,003 | $151K | 12/12/2025 |
| Neil Kumar | ▲ Buy | Option Exercise | 60,975 | — | 12/12/2025 |
| Maricel Apuli | ▼ Sell | Open Market | 2,000 | $149K | 12/8/2025 |
| Neil Kumar | ▼ Sell | Open Market | 7,483 | $552K | 12/5/2025 |
| Neil Kumar | ▼ Sell | Open Market | 12,517 | $914K | 12/5/2025 |
| Neil Kumar | ▼ Sell | Open Market | 12,288 | $898K | 12/5/2025 |
| Neil Kumar | ▼ Sell | Open Market | 7,712 | $569K | 12/5/2025 |
| Neil Kumar | ▼ Sell | Open Market | 2,100 | $154K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 12,200 | $908K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 5,708 | $427K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 5,700 | $426K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 2,100 | $154K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 12,192 | $907K | 12/4/2025 |
| Neil Kumar | ▼ Sell | Open Market | 6,401 | $416K | 11/20/2025 |
| Neil Kumar | ▼ Sell | Open Market | 14,299 | $942K | 11/20/2025 |
| Neil Kumar | ▼ Sell | Open Market | 5,456 | $364K | 11/20/2025 |
| Andrew Lo | ▼ Sell | Open Market | 24,007 | $1.6M | 11/18/2025 |
| Andrew Lo | ▼ Sell | Open Market | 30,993 | $2.0M | 11/18/2025 |
| Thomas Trimarchi | ▼ Sell | Open Market | 6,956 | $465K | 11/17/2025 |
| Andrew Lo | ▼ Sell | Open Market | 36,801 | $2.5M | 11/17/2025 |
| Andrew Lo | ▼ Sell | Open Market | 3,798 | $255K | 11/17/2025 |
| Randal W. Scott | ▲ Buy | Option Exercise | 10,000 | $168K | 11/17/2025 |
| Randal W. Scott | ▼ Sell | Open Market | 3,801 | $252K | 11/17/2025 |
| Randal W. Scott | ▼ Sell | Open Market | 6,199 | $415K | 11/17/2025 |
| Thomas Trimarchi | ▼ Sell | Open Market | 9,978 | $660K | 11/17/2025 |
| Maricel Apuli | ▼ Sell | Tax Withholding | 4,781 | $317K | 11/16/2025 |
| Neil Kumar | ▲ Buy | Option Exercise | 33,544 | — | 11/16/2025 |
| Neil Kumar | ▲ Buy | Option Exercise | 19,599 | — | 11/16/2025 |
| Neil Kumar | ▲ Buy | Option Exercise | 11,554 | — | 11/16/2025 |
| Neil Kumar | ▼ Sell | Tax Withholding | 32,855 | $2.2M | 11/16/2025 |
| Thomas Trimarchi | ▼ Sell | Tax Withholding | 21,317 | $1.4M | 11/16/2025 |
| Hannah Valantine | ▲ Buy | Option Exercise | 25,484 | $1.2M | 11/12/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success
BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.